![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
A 52-Week Phase 3 Clinical Trial of Resmetirom
in 180 Patients With Well-Compensated NASH Cirrhosis
|
|
|
AASLD 2022 Nov 4-8
Stephen A. Harrison,1 Naim Alkhouri,2 Rebecca A. Taub,3 Guy W. Neff,4 Kris V. Kowdley,5 Mazen Noureddin6
1University of Oxford, United Kingdom & Pinnacle Clinical Research, San Antonio, TX; 2Arizona Liver Health, Tucson, AZ; 3Madrigal Pharmaceuticals, Conshohocken, PA; 4Covenant Metabolic Specialists, Sarasota, FL;
5Liver Institute Northwest, Seattle, WA; 6Houston Research Institute, Houston, TX
![1108221](../images/110822/110822-1/1108221.gif)
![1108222](../images/110822/110822-1/1108222.gif)
![1108223](../images/110822/110822-1/1108223.gif)
![1108224](../images/110822/110822-1/1108224.gif)
![1108225](../images/110822/110822-1/1108225.gif)
![1108226](../images/110822/110822-1/1108226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|